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A number of studies focusing on the intestinal mucosa,
its permeability, abnormal gut development, leaky gut,
and other GI problem raised many questions but studies were somehow inconclusive and an expert panel of
American Academy of Pediatrics has strongly recommended further investigation in these areas. GI tract
has a direct connection with the immune system and
an imbalanced immune response is usually seen in ASD
children. Maternal infection or autoimmune diseases
have been suspected. Activation of the immune system
during early development may have deleterious effect
on various organs including the nervous system. In this
review we revisited briefly the GI and immune system
abnormalities and neuropeptide imbalance and their
role in the pathophysiology of ASD and discussed some
future research directions.

Abstract

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Autism spectrum disorders (ASD) comprise a group
of neurodevelopmental abnormalities that begin in
early childhood and are characterized by impairment
of social communication and behavioral problems including restricted interests and repetitive behaviors.
Several genes have been implicated in the pathogenesis of ASD, most of them are involved in neuronal
synaptogenesis. A number of environmental factors
and associated conditions such as gastrointestinal
(GI) abnormalities and immune imbalance have been
linked to the pathophysiology of ASD. According to the
March 2012 report released by United States Centers
for Disease Control and Prevention, the prevalence of
ASD has sharply increased during the recent years and
one out of 88 children suffers now from ASD symptoms. Although there is a strong genetic base for the
disease, several associated factors could have a direct
link to the pathogenesis of ASD or act as modifiers of
the genes thus aggravating the initial problem. Many
children suffering from ASD have GI problems such as
abdominal pain, chronic diarrhea, constipation, vomiting, gastroesophageal reflux, and intestinal infections.

Key words: Autism spectrum disorders; Gastrointestinal
abnormalities; Immune activation; Crohn’s disease;
Neuropeptides; Brain-derived neurotrophic factor; My-
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cobacterium paratuberculosis

Core tip: According to the March 2012 report released
by United States Centers for Disease Control and Prevention there was a 78% increase in the prevalence of
autism spectrum disorders (ASD) during 2002-2008 in
the United States. Although several genes causing ASD
have been discovered, genetic cause of ASD is about
25% of cases. There was not a significant research focus on environmental factors and ASD-associated comorbidities in the last two decades. We revisited the
gastrointestinal (GI) involvement, GI infection, immune
imbalance, maternal infection and immunity, and intestinal microflora in ASD. Some neuropeptides, neurotrophins, their effects, and side effects have also been
discussed.
Samsam M, Ahangari R, Naser SA. Pathophysiology of au-
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while several factors have been implicated in its pathogenesis of autistic disorders. Among these, the genetic
cause has long been implicated to be a strong evidencebased etiology[5,6] in cases of some co-occurring or associated conditions with ASD such as tuberous sclerosis,
fragile X syndrome, Rett syndrome[7] and some other.
Siblings of autistic offspring have a higher incidence of
autism than general population[8] and twin studies have
also indicated strong role for inheritance[9]. There is wide
range of phenotype but more genetically homogeneous
ASD patients present with less phenotypic heterogeneity[10]. In addition, human genetic investigations and animal models[11] of ASD detected de novo copy number
mutations[12-14], and rare variant mutations resulting in
abnormal alleles in the person or close ancestry that influence neuroanatomical and behavioral traits[15]. These
studies have shown dysregulations in genes involved in
synapse function[16]. A comprehensive and informative
review of several genetic studies by Banerjee et al[17] show
abnormal assembly or structure of several transmembrane and scaffolding proteins involved in synaptogenesis
and its maintenance, as well as dysregulation of genes involved in the signal transduction mechanism of synapse
formation are among the major genetic abnormalities of
ASD. Nevertheless, with the discovery of several genes
as well as interactions of multiple genes in one individual,
epigenetic factors, and effects of environmental modifiers on these genes in ASD, genetic causes including the
diagnosable medical conditions, single-gene defect, and
cytogenetic problems comprise 25% of the ASD patients
so far[18-20]. Therefore, a number of clinical phenotypes
and associated co-morbidities have become the characteristic features of ASD[21]. Although some studies indicated
a role for mitochondrial DNA mutation in ASD that may
possibly lead to impairment of mitochondrial energy
metabolism, more research is needed for definitive answers[22]. Mitochondrial dysfunction has been implicated
in several neurological disorders[23,24] and it may have a
role in ASD. Mitochondria has antibacterial immunity[25]
and would be important in case of infections especially
that of the GI tract in ASD children.

tism spectrum disorders: Revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol 2014;
20(29): 9942-9951 Available from: URL: http://www.wjgnet.
com/1007-9327/full/v20/i29/9942.htm DOI: http://dx.doi.
org/10.3748/wjg.v20.i29.9942

INTRODUCTION
Autism spectrum disorders (ASD) comprise a group of
neurodevelopmental abnormalities that begin in early
childhood although the first diagnosis may sometimes
occur later in life and are characterized by problems in
communication and social behavior. According to the 5th
edition of the diagnostic and statistical manual of mental
disorders (DSM-5) diagnostic criteria that has recently
been released, major ASD manifestations include impairment in social communication and behavioral problems
such as fixated (restricted) interests and repetitive behaviors; delay in language and age of onset are not emphasized in DSM-5 diagnostic criteria[1,2].
According to a report by Centers for Disease Control
and Prevention that was released in March 30th 2012, referring to 2008 surveillance year, the prevalence of ASD
among 8 years old children in 14 Autism and Developmental Disabilities Monitoring (ADDM) sites in the United
States is more than 1% (11.3 per 1000 or one per 88 children) and that male/female ratio is approximately 4/1 (ASD
is more seen among boys, 18.4 per 1000, that is one in 54
boys while in girls the prevalence was 4.0 per 1000, that is
one per 252 girls). The report found differences among
race and ethnicity as well, although, the latter findings were
recommended to be interpreted by caution[3] (http://www.
cdc.gov/mmwr/pdf/ss/ss6103.pdf). Nevertheless, the
study shows a 23% increase in the prevalence of ASD from
2006 to 2008 and an overall 78% increase during 2002-2008
among children aged 8 years[3]. The focus of that study by
Centers for Disease Control and Prevention on 8 years old
children is due to the baseline study by CDC demonstrating this age as identified peak prevalence of the disease.
Moreover, ASD evaluation in that report was according to
the DSM-Ⅳ-Text Revision diagnostic criteria that included
the Autistic disorder, Pervasive Developmental DisorderNot Otherwise Specified (PDD-NOS, that includes the
Atypical Autism), or Asperger Disorder. Although DSM-V
criteria that was introduced in 2013 has modified the ASD
diagnostic criteria[2] and the ASD prevalence estimates will
probably be lower under the DSM-Ⅴ criteria[4], the numbers in the statistics given are high and indicate that more
research and effort is needed to investigate the pathomechanism of ASD, it’s treatment, and patient care under new
criteria while continue to support the ASD patients who
were identified under previous diagnostic criteria.

Male to female ratio in ASD
The reason for 4/1 male to female ratio in ASD is not
very well understood but it is very important. Recent
studies implicate some epigenetic phenomena such as
sex-specific effects of Y-linked genes, balanced, as well
as skewed X-inactivation, escaping X-inactivation, and
parent-of-origin allelic gene among others in the etiology
of ASD[26] and heterogeneity in gene regulation at allelic
level as well as total gene expression[27]. These sex differences may be due to genetic and hormonal differences
that could be initiated during early times of development
due to differences in responses to and interactions with
various environmental factors such as diet, stress, infection, and drugs. Due to the involvement of many X-linked
genes involved in placenta formation and placentaspecific epigenetic processes, placenta plays an important

PATHOMECHANISM OF ASD
Genetic causes
The exact pathomechanism of ASD is not known so far
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role in sex-specific responses to environmental factors
and disease states later in life[28]. Internal and external
environmental factors have long been implicated in the
etiology of ASD. Early maternal immune activation may
cause prenatal stress, affecting boys more severely due to
a vulnerable genotype[26].

Other studies that indicated more frequent diarrhea and
other GI symptoms in autistic children reported inconclusive results[39] and that intravenous secretin administration to autistic patients with GI symptoms didn’t improve
their language problem in contrast to other reports[40].
Therefore experts suggested the needs for properly powered investigations[34] in these issues.
GI abnormalities are often seen to correlate with the
severity of the ASD behavioral problems and current
literature favors a gut-brain interaction where GI abnormalities may be involved in the pathogenesis or severity
of ASD[41].
There is high degree of disability when these patients
grow up and studies show only 15% of ASD children
may have a favorable life in adulthood while a great majority of them will have poor or very poor outcomes
when becoming adult[42,43].

NEUROPATHOLOGICAL CHANGES OF
ASD
Both postmortem and neuroimaging studies and animal
models of ASD show abnormalities in different brain
regions such as the frontal cortex, cerebellum, hippocampus, and the amygdaloid nucleus and cerebellothalamo-cortical pathways[29]. One of the neuropathological findings in ASD includes the presence of focal
cortical dysplasias due to possibly the heterochronic
division of germinal cells leading to abnormal migration
of daughter cells to their target regions[30,31]. Abnormal
neuronal migration leads to circumscribed foci of thin
cortical areas in ASD human brain especially in frontal
lobe containing smaller pyramidal neurons and interneurons. These pathological findings have been attributed
to the sensory and motor deficits as well as the epileptic
seizures seen in ASD[30]. Autism-epilepsy phenotype has
recently been shown to be associated with macrocephaly,
a pathologic condition due to accelerating brain growth
in early development leading to ASD[32]. There are evidences that the overall size of the brain is increased in
some cases of ASD[29].

Gut mucosa, absorption, barrier function, permeability,
immune response and oral tolerance
One of the well-established functions of the GI tract
is to break down the structure of the food particles by
digestion and converting them to the smallest molecules.
This digested material will be absorbed by the luminal
surface of intestinal epithelium through various types of
transport mechanisms, and transported into the blood or
lymph capillaries on the other side of the intestinal mucosal cells[44].
GI tract works very closely with the immune system
to maintain homeostasis and protects our body against
microorganisms and foreign antigens.
Intestinal mucosa is continuously challenged by huge
amount of foreign antigens and microorganisms from
environment. The organized regulation of the intestinal
barrier maintains the mucosal immune function and prevents inflammation[45]. In spite of the microorganisms of
the gut flora, various antigens from digested food, and
pathogenic microorganisms, the response of the mucosal
immune system is a controlled physiologic inflammation
that regulates the population of T helper (Th)2 vs Th1
responses[46]. Intestinal epithelial mucosal cells express
classical and non-classical MHC molecules and activate
specific regulatory T cells (Tregs) and therefore, serve as
non-professional antigen-presenting cells[46]. Different elements of our intestinal barrier include the epithelial cell
integrity, mucus production, epithelial paracellular permeability, and innate immune response. Abnormal changes
in these components may lead to inflammatory diseases
of the intestine[45].
There are other cells in the intestinal mucosa, the
microfold (M) cells that are able to engulf bigger molecules[47]. These cells belong to a group of cells forming
the gut associated lymphoid tissue (GULT, which comprise the intestinal lymphoid follicles, the Peyer’s patches
as well) in the mucosa. M cells can pass their engulfed material to the antigen presenting cells such as macrophages
and dendritic cells in the subepithelial tissue that are in
cross talk with lymphocytes, the B cells, for antibody pro-

NON-GENETIC FACTORS IMPLICATED IN
ASD
Several other conditions such as GI abnormalities, inflammation, environmental factors, infection, toxins, diet,
and drugs have been associated with ASD[8,28].

GASTROINTESTINAL ABNORMALITIES IN
ASD
Several studies have indicated a higher prevalence of
gastrointestinal problems such as abdominal pain, constipation, chronic diarrhea, vomiting, and gastroesophageal reflux disease in ASD patients[8], but a nested-case
control study using United Kingdom database indicated
that there was not a considerable association between GI
abnormalities and ASD[33].
A number of other conditions such as GI immune/
inflammation-mediated pathology in ASD or a leaky gut
referring to increased intestinal permeability have not
been established due to limitations and speculations in
those studies[34]. Similarly, studies referring to leaky intestinal epithelium and damaged tight junctions and passage
of dietary gluten or casein or digestion product through
intestinal barrier into the blood stream causing immunogenic responses in the brain were not conclusive[8,35-38].

WJG|www.wjgnet.com
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control patients with GI disturbances had the bacteria[61].
Clostridium bolteae, a bacterium that was shown to be immunogenic in rabbits, is often found in the intestine of
the ASD children and was proposed to possibly be aggravating the GI symptoms in ASD patient[62]. The first
reported case of enterovirus encephalitis linked to or
possibly causing ASD in a 32-mo-old child has been recently published[63].
As mentioned earlier, there are several reports about
the increased permeability or leaky intestine in ASD patients but more research and convincing data is needed
therefore, we think this area of research deserves more
work due to various GI symptoms in ASD patients. However, it is well known that infections can lead to increased
permeability and GI symptoms and beyond. Since ASD
children are often reported to have GI infection and diarrhea and that the immune system is imbalanced in ASD
patients due to a direct relation of the GI mucosa with
the immune system (see the following section) it is necessary to do more research to better understand the GI
mucosal environment and barrier activity, subepithelial
tissue, susceptibility to infection, causative agents, and the
immune response in ASD patients in order to treat them
more effectively.

duction (i.e., intestinal IgA) and are also responsible for
oral tolerance towards the ingested material through other
classes of immunoglobulins and cytokines[44].
Although larger molecules may get into the circulatory system[48], the amount of material that M cells take in
under normal conditions seems to be small compared to
the epithelial lining of the intestine. Nevertheless, when
single unites of lipids are being absorbed by the intestinal cells they can reassemble and bound to lipoproteins,
forming large molecules such as chylomicrons that leave
the intestinal cells through vesicular transport to the extracellular space into the lymph capillaries (due to having
larger fenestration) in the subepithelial tissue to larger
lymphatic vessels and finally into circulation[44,49]. A similar path for other larger molecule is possible.
We have shown that small proteins such as green
fluorescent protein (GFP) bound to cholera toxin-B
(CTB) subunit is able to get into intestinal epithelial cells
in large amounts “by binding to ganglioside M1 (GM1)
receptor[50]’’ and find its way into the blood stream and be
found in the liver and the spleen[51]. In a series of studies
we aimed to introduce large amount of bigger peptides
(such as proinsulin) to induce oral tolerance towards the
protein and treat autoimmune diseases such as diabetes,
by converting the Th1 response to Th2 response with its
associated cytokines[52].
The cholera toxin-A subunit which is the toxic part
attaches to the intestinal cells by means of its CTB subunit, increasing the permeability of the intestinal mucosa
that eventually disrupts the Cl- transport and other ionic
and water transport disturbances leading to diarrhea[53].
Several reports indicate GI infection in ASD patients. GI
infections can increase intestinal permeability.
E. coli bacteria is able to enter the intestinal cells,
change the actin dynamics, modulate the immune response and disrupt the tight junctions, leading to a compromised barrier and increased intestinal permeability
resulting in diarrhea[54]. Interferon-beta (INFβ) has been
shown to protect the intestinal barrier while tumor necrosis factor-alpha (TNF-α) disrupts such barrier through
inhibition of INFβ by another molecule[54]. Other inflammatory conditions such as Crohn’s disease are also able to
increase intestinal permeability[55] but also the increased
baseline permeability in some at risk individuals and
exaggeration to environmental stimuli may increase the
chance of Crohn’s disease[56]. Frequent intestinal infections in ASD patients have been reported.
Several factors have been implicated in the pathogenesis of Crohn’s disease. Micobacterium paratuberclosis
(MAP) has been found in the milk, blood and surgical
tissue samples of individuals suffering from Crohn’s
disease[57-59]. MAP due to having a molecular mimicry to
heat shock proteins has been postulated to be involved in
the pathogenesis of ASD by stimulating antibodies that
may cross react with the nervous system myelin basic
protein[60].
Sutterella species have recently been found in the
ileum of ASD patients with GI abnormalities while no

WJG|www.wjgnet.com

IMMUNE SYSTEM IMBALANCE IN ASD
Other co-morbid conditions in ASD such as inflammation, inflammatory response, and immune activation have
long been implicated in the pathogenesis of ASD but
studies so far were not conclusive[21,64,65]. A number of
studies reveal abnormalities of the peripheral immune
system supporting the ides of immune involvement in
ASD however, immune abnormalities such as activation
of microglial cells and innate neuroimmune system are
also found in the brain and cerebrospinal fluid (CSF) of
ASD patient, the neuroinflammation[66].
Neuroimmune abnormalities have been recently
reviewed elsewhere[43]. Blood brain barrier (BBB) is an
important regulator of the brain homeostasis[67]. There
are evidences that the BBB function is altered in ASD
children due to neurological inflammation, immune dysregulation and increased inflammatory cytokines in the
brain[68]. Immune response abnormalities are seen in the
GI tract and other tissues, the peripheral blood, and in
the central nervous system (CNS) of the ASD patients.
On the other hand, maternal infection or inflammation,
and autoimmune diseases of the family of ASD children
have also been shown to cause immune problems in the
offspring. We discuss that briefly as maternal immune activation in the following section.
Significantly lower subpopulation of CD4+ and CD8+
lymphocyte as well as imbalance between Th1 and Th2like cytokines have been observed in autism[69]. Several
interleukins (ILs) and IFN-gamma imbalance has been
reported in the peripheral blood of ASD children with
increased activation of both Th1 and Th2 pathways leaning more towards Th2 arm[70]. The immunoglobulins are
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phospholipid antibodies have been linked with psychological problems such as cognitive malfunction, repetitive
behavior and anxiety. Increased levels of anti-cardiolipin,
bate 2-glycoprotein 1, and anti-phospholipid antibodies
were found in the blood plasma of the ASD children
compared to their age matched typically developing children and the DD children[84].
Results of the animal studies indicate that the behavioral and maternal immune activation are different among
different mice species referring to the possibility that a
subpopulation of human might be more vulnerable to
particular environmental agents[85].
Maternal immune activation due to infections, inflammatory diseases and autoimmune diseases can have a deleterious effect on the fetus by affecting fetal tissue and its
consequences during postnatal period. This area deserves
more focus. Animal models of ASD especially the infection models can be very informative.

also reported to be imbalanced in the serum of ASD
children. Total serum protein was significantly increased
in autistic patients referring to increased albumin and
gamma globulin, as well as increased serum IgG, IgG2
and IgG4 that was attributed to possibly an underlying
autoimmune disorder and/or increased vulnerability to
infections[71]. A number of other immune abnormalities have also been reported in ASD[24]. The immune
system is activated in many neurological and psychiatric
disorders including those with genetic abnormalities and
growing evidence shows that these neurological disorders
are aggravated by the immune system activation leading
to worsening of the initial disease[72,73] although immune
cells have beneficial effects as well[74].
Immune system has several beneficial effects protecting us from microorganisms and helps destroying the
tumor cells or disrupting their growth. Immunotherapy
has been an effective approach that uses molecules of the
body’s own immune system to interfere with the growth
of cancer cells and is being used in the treatment of brain
tumors such as metastatic melanomas[67,75]. Nevertheless, what we see in case of neurological and psychiatric
disorders is mostly the deleterious effect of the immune
activation against brain tissue and its related structures.
Since the Th2 pathway produces more immunosuppressory cytokines compared to Th1 arm that favors
more the pro-inflammatory cytokines, and both arms are
reportedly activated with a predominant Th2 arm in ASD
patients, it might help the body tolerate and not to react
towards many antigens (possibly penetrated through GI
tract), but these antigens can have deleterious effect on
other tissues such as brain. More research is needed to
understand the role of immune system in ASD.

MICROBIOTA IN ASD
Microbiota is an emerging topic that has attracted several
researchers to look for the possible connection between
the GI microflora and behavioral abnormalities. Earlier
repot of deficient disaccharidase enzymatic activity in
ASD children and GI symptom[86] prompted investigations looking for intestinal mucosal microbiota involved
in carbohydrate metabolism. Abnormal carbohydrate
digestion and transport and mucosal dysbiosis (imbalance
in the intestinal microbial ecosystem) was reported in the
ASD children[87].
Gut dysbiosis was proposed to be involved in the
pathogenesis of several diseases[88]. Reduced level of fermenters has been found in the intestinal microflora of
the ASD patients[89]. The microbiota-gut-brain axis refers
to the ability of gut microbiota to communicate with
brain and regulate behavior[90]. Fecal microbiota transplantation has been used in treating several GI disorders
but increase knowledge and control trials are needed before it can be used broadly in clinic[91].
Nevertheless, other studies didn’t find a difference
in GI microbiota of ASD children with and without GI
disturbances[92]. Imbalance in gut microbiota population
may render the intestinal mucosa susceptible to injuries,
infections, inflammation, abnormal digestion, immune
imbalance, immune reaction and cross reaction in other
tissues including the brain. More research is emerging in
this area.

MATERNAL IMMUNE ACTIVATION AND
ASD
Many studies show alteration of immune system and an
imbalance of various cytokines in ASD children[76,77]. A
number of studies show a link between ASD and a family history of autoimmune diseases or those families with
altered inflammatory cytokines or other immune problems[76,78]. The autoimmune hypothesis and development
of the mental disorders has long existed[79].
When antibodies developed in immune-mediated
disorders were introduced to pregnant monkeys, the offspring showed behavioral changes and CNS pathology[80].
Perinatal exposure to infection has been implicated in the
pathogenesis of ASD and schizophrenia[81]. Activation of
the immune system in pregnant mice leads to the activation of macrophages in the offspring[82].
A recent study investigating the role of maternal autoimmune disease, asthma, and allergy on developmental
disorders looked at 560 ASD patients and 168 cases of
developmental delay without autism (DD) has found a
significant modest increase in both the ASD and DD
combined (the ASD alone data was not significant) in
the children of sick mothers during pregnancy[83]. Anti-

WJG|www.wjgnet.com

VASOACTIVE INTESTINAL PEPTIDE AND
OTHER NEUROPEPTIDES IN ASD
Elevated levels of several neuropeptide including vasoactive intestinal peptide (VIP), calcitonin gene-related peptide (CGRP), brain-derived neurotrophic factor (BDNF)
and neurotrophin 4/5 (NT4/5) in the blood of 60 neonates who were just born compared to 56 age-matched
control group[93] opened many lines of investigation.
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Those 60 neonates developed ASD or mental retardation
later in life. Nelson and colleagues looked at their blood
in the archived neonatal blood samples that are usually
drawn at birth.
VIP and pituitary adenylate cyclase-activating peptide (PACAP) are members of the VIP-glucagonsecretin family of peptides[94]. VIP has several functions
in the digestive tract, cardiovascular system, lungs, kidney, and endocrine system[95] and is involved in cerebral
growth and neurogenesis and astrocytogenesis[8]. VIP is
a parasympathetic neurotransmitter and neuromodulator that has been implicated in the pathogenesis of cluster headaches[96].
VIP is involved in activation of brainstem reflexes,
and its infusion was shown to decrease the blood velocity in the middle cerebral artery. VIP/PACAP have been
implicated in homeostasis of the immune system and are
believed to have anti-inflammatory effect on innate and
adaptive immunity, promote Th2 responses and decrease
the proinflammatory Th1 response[97,98]. Several properties of VIP including those mentioned above and its
function on intestinal tight junctions and permeability, as
well as therapeutic use have been recently reviewed[99].
BDNF is a well-known neurotrophic factor of the
nerve growth factor family together with other neurotrophins that acts mainly on high affinity tyrosine kinase
(Trk)B receptor but also like all other family members
acts on the low affinity neurotrophin receptor, the p75
receptor.
Low concentration of BDNF is able to excite neurons in cerebral cortex, cerebellum, and the hippocampus[100]. BDNF and NT4/5 were able to depolarize brain
neurons as rapidly as glutamate (one of the strongest
excitatory neurotransmitters) at 1000-fold lower concentrations[100]. BDNF deficiency has been implicated in a
number of psychiatric disorders and ASD including their
animal models[101,102].
Although neurotrophic factors are important for
neuronal survival, they can have adverse effects as well.
It is not known why BDNF is increased in the blood of
infants in Nelson’s study. Although the trophic effects
of the neurotrophic factors is very well known and low
levels of BDNF has been reported in some psychiatric
diseases and ASD[103,104] a recent study on mice overexpressing BDNF shows that the animals found abnormal
behavior by age[105]. As mentioned above, if BDNF is
1000 fold stronger than glutamic acid in exciting neurons[100] the adverse effect of overexpression might be
due to excitotoxicity and possible neuronal degeneration;
those mice suffered from epilepsy[105].
BDNF acting on p75 receptor causes axonal degeneration[106] which is used during normal development when
some sprout should be eliminated. Another study shows
that BDNF has increased the spasticity in spinal cord injured mice[107]. BDNF has been reported to activate glutamate receptors[108] and this might cause excitotoxicity[109].
Moreover, BDNF mediates nociceptive plasticity[110] and
was found to initiate and maintain a chronic pain state[111]
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and that BDNF enhances the excitability of small diameter trigeminal ganglion neurons[112].
Neurotrophic factors may not be stable at normal
body temperature, are expensive as recombinant proteins
and therefore several animal studies have introduced
neurotrophic factor genes through injection of viral vectors into animal tissue which make the amount of gene
product (protein) thus the dosage difficult to predict,
while immunity of the host against the virus is a major
problem usually in gene therapy.
CGRP is a neuromodulator/neurotransmitter peptide that is found in tissues including the nervous tissue.
It is a sensory neuropeptide that coexists usually with
glutamate and substance P and neurokinin A (NKA) in
sensory neurons[113]. It is a vasodilator peptide and causes
hyperemia in some pathological conditions and has been
implicated in the pathogenesis of migraine[114]. Its receptors are found on blood vessels and axons and neurons in
several tissues including the central nervous system.
CGRP has been found elevated in the peripheral
blood of migraine patients[115]. CGRP receptor antagonists are the gepant family of drugs such as Olcegepant
and Telcagepant, and B144370TA, are some of the newest antimigraine drugs that lack vasoconstrictive activity
and were thought to overcome some of the adverse effect of the Triptan family of drugs (serotonin 1B/D receptor agonists), but elevated liver enzymes and other side
effects have been observed and drugs are still in clinical
trials phase Ⅱ and Ⅲ[114,116,117]. CGRP potently enhanced
BDNF release from trigeminal ganglion neuronal culture
indicating that BDNF might be a mediator of nociceptive plasticity[98,110].
It is not known precisely why neuropeptide levels are
increased in newborn children that later develop ASD.
Elevated neuropeptide levels might be due to inflammation, or compensation and restoration of neuronal or
other tissues homeostasis in ASD infants. This merits a
thorough investigation to see their role in ASD.

CONCLUSION
Although ASD has a strong genetic base, GI abnormalities and immune imbalance as part of the environmental
factors have been implicated in the pathogenesis of ASD.
A number of GI abnormalities such as abdominal pain,
diarrhea, constipation, gastroesophageal reflux, and GI
infections have been reported in ASD patient but a clear
and convincing link of these symptoms to ASD has not
yet been found.
An expert panel of American Academy of Pediatrics[34] has strongly recommended further investigation in
the role of GI abnormalities in the pathophysiology of
ASD. As we discussed, the GI disturbances are directly
related to the immune system. Immune imbalances are
common in ASD patients. GI infections can also activate
the immune system in ASD patients. Maternal autoimmune disease and infections can also cause damage to the
embryonic/fetal tissues and aggravate a genetic problem
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in ASD if not causing the damage to the nervous system.
The significant increase in the prevalence of ASD (at
least 78% from 2002-2008) in the United States reported
by the Center for Disease Control and Prevention in 2012
is a strong indication for revisiting critically every possible
factor and look for possible clues in order to slow down
or prevent this sharp increase in the prevalence of ASD
in our young population and find more therapeutic opportunities to treat ASD more efficiently.
Increased VIP and other neuropeptides in ASD
newborns were discussed briefly but this area certainly
deserves more exploration and conclusive studies on how
to proceed with the findings. Decreased BDNF has been
shown later in life in ASD and other mental disorder patients, but its administration although may have positive
effects, may also have adverse effects and neurotoxicity
on the already compromised nervous tissue in ASD and
other diseases that should be taken into consideration.
We have not discussed several other factors that have
been linked to ASD such as impairment in gut development[8] or autonomic dysfunction[43] or other factors.

10

11

12

13

14

REFERENCES
1
2

3

4

5

6
7

8
9

Lauritsen MB. Autism spectrum disorders. Eur Child Adolesc
Psychiatry 2013; 22 Suppl 1: S37-S42 [PMID: 23300017 DOI:
10.1007/s00787-012-0359-5]
Grzadzinski R, Huerta M, Lord C. DSM-5 and autism
spectrum disorders (ASDs): an opportunity for identifying
ASD subtypes. Mol Autism 2013; 4: 12 [PMID: 23675638 DOI:
10.1186/2040-2392-4-12]
Autism and Developmental Disabilities Monitoring
Network Surveillance Year 2008 Principal Investigators;
Centers for Disease Control and Prevention. Prevalence of
autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.
MMWR Surveill Summ 2012; 61: 1-19 [PMID: 22456193]
Maenner MJ, Rice CE, Arneson CL, Cunniff C, Schieve LA,
Carpenter LA, Van Naarden Braun K, Kirby RS, Bakian AV,
Durkin MS. Potential impact of DSM-5 criteria on autism
spectrum disorder prevalence estimates. JAMA Psychiatry
2014; 71: 292-300 [PMID: 24452504 DOI: 10.1001/jamapsychiatry.2013.3893]
Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM,
Caronna EB, Miller KJ, Frazier JA, Silverstein I, Picker J,
Weissman L, Raffalli P, Jeste S, Demmer LA, Peters HK,
Brewster SJ, Kowalczyk SJ, Rosen-Sheidley B, McGowan C,
Duda AW, Lincoln SA, Lowe KR, Schonwald A, Robbins M,
Hisama F, Wolff R, Becker R, Nasir R, Urion DK, Milunsky
JM, Rappaport L, Gusella JF, Walsh CA, Wu BL, Miller DT.
Clinical genetic testing for patients with autism spectrum
disorders. Pediatrics 2010; 125: e727-e735 [PMID: 20231187
DOI: 10.1542/peds.2009-1684]
Silver WG, Rapin I. Neurobiological basis of autism. Pediatr Clin North Am 2012; 59: 45-61, x [PMID: 22284792 DOI:
10.1016/j.pcl.2011.10.010]
Betancur C, Sakurai T, Buxbaum JD. The emerging role of
synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009; 32: 402-412
[PMID: 19541375 DOI: 10.1016/j.tins.2009.04.003]
White JF. Intestinal pathophysiology in autism. Exp Biol Med
(Maywood) 2003; 228: 639-649 [PMID: 12773694]
Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E,
Yuzda E, Rutter M. Autism as a strongly genetic disorder:
evidence from a British twin study. Psychol Med 1995; 25:

WJG|www.wjgnet.com

15
16

17

18
19

20
21

22

23

24
25

9948

63-77 [PMID: 7792363]
Bruining H, de Sonneville L, Swaab H, de Jonge M, Kas M,
van Engeland H, Vorstman J. Dissecting the clinical heterogeneity of autism spectrum disorders through defined
genotypes. PLoS One 2010; 5: e10887 [PMID: 20526357 DOI:
10.1371/journal.pone.0010887]
Shinoda Y, Sadakata T, Furuichi T. Animal models of autism
spectrum disorder (ASD): a synaptic-level approach to autistic-like behavior in mice. Exp Anim 2013; 62: 71-78 [PMID:
23615300]
Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C,
Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J, Leotta A,
Pai D, Zhang R, Lee YH, Hicks J, Spence SJ, Lee AT, Puura K,
Lehtimäki T, Ledbetter D, Gregersen PK, Bregman J, Sutcliffe
JS, Jobanputra V, Chung W, Warburton D, King MC, Skuse D,
Geschwind DH, Gilliam TC, Ye K, Wigler M. Strong association of de novo copy number mutations with autism. Science
2007; 316: 445-449 [PMID: 17363630]
Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge
KD, Rutledge SL, Korf BR, Carroll AJ. Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay,
mental retardation, and/or autism spectrum disorders. Am
J Med Genet A 2011; 155A: 2386-2396 [PMID: 22031302 DOI:
10.1002/ajmg.a.34177]
Ronemus M, Iossifov I, Levy D, Wigler M. The role of de
novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet 2014; 15: 133-141 [PMID: 24430941 DOI:
10.1038/nrg3585]
Malhotra D, Sebat J. CNVs: harbingers of a rare variant
revolution in psychiatric genetics. Cell 2012; 148: 1223-1241
[PMID: 22424231 DOI: 10.1016/j.cell.2012.02.039]
Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual
disabilities. Cold Spring Harb Perspect Biol 2012; 4: [PMID:
22258914 DOI: 10.1101/cshperspect.a009886]
Banerjee S, Riordan M, Bhat MA. Genetic aspects of autism
spectrum disorders: insights from animal models. Front
Cell Neurosci 2014; 8: 58 [PMID: 24605088 DOI: 10.3389/fncel.2014.00058]
Muhle R, Trentacoste SV, Rapin I. The genetics of autism.
Pediatrics 2004; 113: e472-e486 [PMID: 15121991]
Betancur C. Etiological heterogeneity in autism spectrum
disorders: more than 100 genetic and genomic disorders and
still counting. Brain Res 2011; 1380: 42-77 [PMID: 21129364
DOI: 10.1016/j.brainres.2010.11.078]
Miles JH. Autism spectrum disorders--a genetics review.
Genet Med 2011; 13: 278-294 [PMID: 21358411 DOI: 10.1097/
GIM.0b013e3181ff67ba]
Jyonouchi H, Geng L, Streck DL, Toruner GA. Immunological characterization and transcription profiling of peripheral
blood (PB) monocytes in children with autism spectrum
disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation 2012; 9: 4
[PMID: 22226452 DOI: 10.1186/1742-2094-9-4]
Álvarez-Iglesias V, Mosquera-Miguel A, Cuscó I, Carracedo Á, Pérez-Jurado LA, Salas A. Reassessing the role
of mitochondrial DNA mutations in autism spectrum disorder. BMC Med Genet 2011; 12: 50 [PMID: 21470425 DOI:
10.1186/1471-2350-12-50]
Knott AB, Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann N Y Acad Sci 2008; 1147: 283-292 [PMID: 19076450
DOI: 10.1196/annals.1427.030]
Randolph-Gips M, Srinivasan P. Modeling autism: a systems biology approach. J Clin Bioinforma 2012; 2: 17 [PMID:
23043674 DOI: 10.1186/2043-9113-2-17]
West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11: 389-402 [PMID:
21597473 DOI: 10.1038/nri2975]

August 7, 2014|Volume 20|Issue 29|

Samsam M et al . Gastrointestinal and immune involvement in autism
26

27

28

29
30

31

32

33

34

35

36

37

38
39

40

41

Schaafsma SM, Pfaff DW. Etiologies underlying sex differences in Autism Spectrum Disorders. Front Neuroendocrinol 2014; 35: 255-271 [PMID: 24705124 DOI: 10.1016/
j.yfrne.2014.03.006]
Ben-David E, Shohat S, Shifman S. Allelic expression analysis in the brain suggests a role for heterogeneous insults affecting epigenetic processes in autism spectrum disorders.
Hum Mol Genet 2014; 23: 4111-4124 [PMID: 24659497]
Gabory A, Roseboom TJ, Moore T, Moore LG, Junien
C. Placental contribution to the origins of sexual dimorphism in health and diseases: sex chromosomes and epigenetics. Biol Sex Differ 2013; 4: 5 [PMID: 23514128 DOI:
10.1186/2042-6410-4-5]
Santangelo SL, Tsatsanis K. What is known about autism:
genes, brain, and behavior. Am J Pharmacogenomics 2005; 5:
71-92 [PMID: 15813671]
Casanova MF, El-Baz AS, Kamat SS, Dombroski BA, Khalifa
F, Elnakib A, Soliman A, Allison-McNutt A, Switala AE.
Focal cortical dysplasias in autism spectrum disorders.
Acta Neuropathol Commun 2013; 1: 67 [PMID: 24252498 DOI:
10.1186/2051-5960-1-67]
Casanova MF. Autism as a sequence: from heterochronic
germinal cell divisions to abnormalities of cell migration and
cortical dysplasias. Med Hypotheses 2014; 83: 32-38 [PMID:
24780284 DOI: 10.1016/j.mehy.2014.04.014]
Marchese M, Conti V, Valvo G, Moro F, Muratori F, Tancredi R, Santorelli FM, Guerrini R, Sicca F. Autism-epilepsy
phenotype with macrocephaly suggests PTEN, but not
GLIALCAM, genetic screening. BMC Med Genet 2014; 15: 26
[PMID: 24580998 DOI: 10.1186/1471-2350-15-26]
Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database.
BMJ 2002; 325: 419-421 [PMID: 12193358 DOI: 10.1136/
bmj.325.7361.419]
Buie T, Campbell DB, Fuchs GJ, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL,
Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi
H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray
KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer
L, Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus
report. Pediatrics 2010; 125 Suppl 1: S1-18 [PMID: 20048083
DOI: 10.1542/peds.2009-1878C]
D’Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L,
Zaccagnini M, Cardi E, Giardini O. Abnormal intestinal
permeability in children with autism. Acta Paediatr 1996; 85:
1076-1079 [PMID: 8888921 DOI: 10.1111/j.1651-2227.1996.
tb14220.x]
Millward C, Ferriter M, Calver S, Connell-Jones G. Glutenand casein-free diets for autistic spectrum disorder. Cochrane
Database Syst Rev 2008; 2: CD003498 [PMID: 18425890 DOI:
10.1002/14651858.CD003498.pub3]
Goodwin MS, Cowen MA, Goodwin TC. Malabsorption
and cerebral dysfunction: a multivariate and comparative
study of autistic children. J Autism Child Schizophr 1971; 1:
48-62 [PMID: 5172439 DOI: 10.1007/BF01537742]
Dohan FC. Hypothesis: genes and neuroactive peptides
from food as cause of schizophrenia. Adv Biochem Psychopharmacol 1980; 22: 535-548 [PMID: 6994444]
Lightdale JR, Hayer C, Duer A, Lind-White C, Jenkins S,
Siegel B, Elliott GR, Heyman MB. Effects of intravenous
secretin on language and behavior of children with autism
and gastrointestinal symptoms: a single-blinded, open-label
pilot study. Pediatrics 2001; 108: E90 [PMID: 11694674 DOI:
10.1542/peds.108.5.e90]
Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald
JF, McDougle CJ. Gastrointestinal factors in autistic disorder:
a critical review. J Autism Dev Disord 2005; 35: 713-727 [PMID:
16267642 DOI: 10.1007/s10803-005-0019-4]

WJG|www.wjgnet.com

42

43

44
45

46

47

48
49
50

51

52

53
54

55

56

57

58

9949

Hsiao EY. Gastrointestinal issues in autism spectrum disorder. Harv Rev Psychiatry 2014; 22: 104-111 [PMID: 24614765
DOI: 10.1097/HRP.0000000000000029]
Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. Trajectory of development in adolescents and adults with autism.
Ment Retard Dev Disabil Res Rev 2004; 10: 234-247 [PMID:
15666341 DOI: 10.1002/mrdd.20038]
Goyal DK, Miyan JA. Neuro-immune abnormalities in autism and their relationship with the environment: a variable
insult model for autism. Front Endocrinol (Lausanne) 2014; 5:
29 [PMID: 24639668]
Samsam M. Functionally Oriented Regional Anatomy. 2nd
ed. Plymouth, MI: Hayden McNeil publishing, 2013: 209-302
Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT.
Central role of the gut epithelial barrier in the pathogenesis
of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013; 4: 280
[PMID: 24062746]
Rabinowitz K, Mayer L. Working out mechanisms of
controlled/physiologic inflammation in the GI tract. Immunol Res 2012; 54: 14-24 [PMID: 22466933 DOI: 10.1007/
s12026-012-8315-5]
Kernéis S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer’s patch lymphocytes of human enterocytes
into M cells that transport bacteria. Science 1997; 277: 949-952
[PMID: 9252325 DOI: 10.1126/science.277.5328.949]
Hemmings WA, Williams EW. Transport of large breakdown products of dietary protein through the gut wall. Gut
1978; 19: 715-723 [PMID: 680603 DOI: 10.1136/gut.19.8.715]
Dixon JB. Mechanisms of chylomicron uptake into lacteals. Ann N Y Acad Sci 2010; 1207 Suppl 1: E52-E57 [PMID:
20961306 DOI: 10.1111/j.1749-6632.2010.05716.x]
Lencer WI. Microbes and microbial Toxins: paradigms for
microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin. Am J
Physiol Gastrointest Liver Physiol 2001; 280: G781-G786 [PMID:
11292584]
Limaye A, Koya V, Samsam M, Daniell H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. FASEB J 2006; 20: 959-961 [PMID: 16603603
DOI: 10.1096/fj.05-5134fje]
Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H.
Expression of cholera toxin B-proinsulin fusion protein in
lettuce and tobacco chloroplasts--oral administration protects against development of insulitis in non-obese diabetic
mice. Plant Biotechnol J 2007; 5: 495-510 [PMID: 17490448
DOI: 10.1111/j.1467-7652.2007.00259.x]
Muanprasat C, Chatsudthipong V. Cholera: pathophysiology and emerging therapeutic targets. Future Med Chem 2013;
5: 781-798 [PMID: 23651092 DOI: 10.4155/fmc.13.42]
Enteropathogenic Escherichia coli Inhibits Type I Interferonand RNase L-Mediated Host Defense To Disrupt Intestinal
Epithelial Cell Barrier Function. Infect Immun 2014; 82:
2802-2814 [PMID: 24733098]
Wyatt J, Oberhuber G, Pongratz S, Püspök A, Moser G,
Novacek G, Lochs H, Vogelsang H. Increased gastric and
intestinal permeability in patients with Crohn’s disease. Am
J Gastroenterol 1997; 92: 1891-1896 [PMID: 9382060]
Meddings JB. Review article: Intestinal permeability in
Crohn’s disease. Aliment Pharmacol Ther 1997; 11 Suppl
3: 47-53; discussion 53-56 [PMID: 9467978 DOI: 10.1111/
j.1365-2036.1997.tb00808.x]
Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium
avium subsp paratuberculosis from breast milk of Crohn’
s disease patients. Am J Gastroenterol 2000; 95: 1094-1095
[PMID: 10763975 DOI: 10.1111/j.1572-0241.2000.01954.x]
Naser SA, Ghobrial G, Romero C, Valentine JF. Culture
of Mycobacterium avium subspecies paratuberculosis
from the blood of patients with Crohn’s disease. Lancet

August 7, 2014|Volume 20|Issue 29|

Samsam M et al . Gastrointestinal and immune involvement in autism

59

60
61

62

63

64
65
66

67
68
69

70

71

72

73
74

75

2004; 364: 1039-1044 [PMID: 15380962 DOI: 10.1016/S01406736(04)17058-X]
Romero C, Hamdi A, Valentine JF, Naser SA. Evaluation of
surgical tissue from patients with Crohn’s disease for the
presence of Mycobacterium avium subspecies paratuberculosis DNA by in situ hybridization and nested polymerase
chain reaction. Inflamm Bowel Dis 2005; 11: 116-125 [PMID:
15677904 DOI: 10.1097/00054725-200502000-00004]
Dow CT. Mycobacterium paratuberculosis and autism:
is this a trigger? Med Hypotheses 2011; 77: 977-981 [PMID:
21903338 DOI: 10.1016/j.mehy.2011.08.024]
Williams BL, Hornig M, Parekh T, Lipkin WI. Application
of novel PCR-based methods for detection, quantitation, and
phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 2012; 3: pii: e00261-11 [PMID:
22233678 DOI: 10.1128/mBio.00261-11]
Pequegnat B, Sagermann M, Valliani M, Toh M, Chow H,
Allen-Vercoe E, Monteiro MA. A vaccine and diagnostic target for Clostridium bolteae, an autism-associated bacterium.
Vaccine 2013; 31: 2787-2790 [PMID: 23602537 DOI: 10.1016/
j.vaccine.2013.04.018]
Marques F, Brito MJ, Conde M, Pinto M, Moreira A. Autism
spectrum disorder secondary to enterovirus encephalitis. J
Child Neurol 2014; 29: 708-714 [PMID: 24782421 DOI: 10.1177
/0883073813508314]
Ashwood P, Wills S, Van de Water J. The immune response
in autism: a new frontier for autism research. J Leukoc Biol
2006; 80: 1-15 [PMID: 16698940 DOI: 10.1189/jlb.1205707]
Singh VK. Phenotypic expression of autoimmune autistic
disorder (AAD): a major subset of autism. Ann Clin Psychiatry 2009; 21: 148-161 [PMID: 19758536]
Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry
2005; 17: 485-495 [PMID: 16401547 DOI: 10.1080/0264683050
0381930]
Samsam M. Editorial: central nervous system drugs in the
treatment of neurological disorders. Cent Nerv Syst Agents
Med Chem 2012; 12: 153-157 [PMID: 22894608]
Noriega DB, Savelkoul HF. Immune dysregulation in autism spectrum disorder. Eur J Pediatr 2014; 173: 33-43 [PMID:
24297668 DOI: 10.1007/s00431-013-2183-4]
Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998; 85: 106-109 [PMID: 9627004 DOI: 10.1016/
S0165-5728(98)00021-6]
Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, Altaye M, Wills-Karp M.
Elevated cytokine levels in children with autism spectrum
disorder. J Neuroimmunol 2006; 172: 198-205 [PMID: 16360218
DOI: 10.1016/j.jneuroim.2005.11.007]
Croonenberghs J, Wauters A, Devreese K, Verkerk R,
Scharpe S, Bosmans E, Egyed B, Deboutte D, Maes M.
Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol
Med 2002; 32: 1457-1463 [PMID: 12455944 DOI: 10.1017/
S0033291702006037]
Kobsar I, Berghoff M, Samsam M, Wessig C, Mäurer M,
Toyka KV, Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the
recombination activating gene-1. Brain 2003; 126: 804-813
[PMID: 12615640 DOI: 10.1093/brain/awg072]
Samsam M. Role of inflammation in neurological and psychiatric disorders, editorial. AIAA-MC 2010; 3: 166-169
Berghoff M, Samsam M, Müller M, Kobsar I, Toyka KV,
Kiefer R, Mäurer M, Martini R. Neuroprotective effect of the
immune system in a mouse model of severe dysmyelinating
hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 2005;
28: 118-127 [PMID: 15607947 DOI: 10.1016/j.mcn.2004.09.001]

WJG|www.wjgnet.com

76

77

78

79
80
81

82

83

84

85

86

87

88

89

90

91

9950

Allen T, Gundrajakuppam L. A role of immunotherapy in
metastatic malignant melanoma. Cent Nerv Syst Agents Med
Chem 2012; 12: 182-188 [PMID: 22697295]
Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA,
Procházka V, Melamed M, Kristt DA, Steinberg A, Shulman
C, Hwang P, Koren G, Walfisch A, Passweg JR, Snowden JA,
Tamouza R, Leboyer M, Farge-Bancel D, Ashwood P. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 2013; 44: 1-7 [PMID: 23867105
DOI: 10.1016/j.jaut.2013.05.005]
Goines PE, Ashwood P. Cytokine dysregulation in autism
spectrum disorders (ASD): possible role of the environment.
Neurotoxicol Teratol 2013; 36: 67-81 [PMID: 22918031 DOI:
10.1016/j.ntt.2012.07.006]
Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in
probands with pervasive developmental disorders. Pediatrics
2003; 112: e420 [PMID: 14595086]
Sakić B, Szechtman H, Denburg JA. Neurobehavioral alterations in autoimmune mice. Neurosci Biobehav Rev 1997; 21:
327-340 [PMID: 9168268]
Libbey JE, Fujinami RS. Role for antibodies in altering behavior and movement. Autism Res 2010; 3: 147-152 [PMID:
20589715 DOI: 10.1002/aur.144]
Meyer U, Feldon J, Dammann O. Schizophrenia and autism:
both shared and disorder-specific pathogenesis via perinatal
inflammation? Pediatr Res 2011; 69: 26R-33R [PMID: 21289540
DOI: 10.1203/PDR.0b013e318212c196]
Onore CE, Schwartzer JJ, Careaga M, Berman RF, Ashwood
P. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun 2014; 38:
220-226 [PMID: 24566386 DOI: 10.1016/j.bbi.2014.02.007]
Lyall K, Ashwood P, Van de Water J, Hertz-Picciotto I. Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. J Autism Dev Disord 2014; 44:
1546-1555 [PMID: 24337796]
Careaga M, Hansen RL, Hertz-Piccotto I, Van de Water
J, Ashwood P. Increased anti-phospholipid antibodies in
autism spectrum disorders. Mediators Inflamm 2013; 2013:
935608 [PMID: 24174712 DOI: 10.1155/2013/935608]
Schwartzer JJ, Careaga M, Onore CE, Rushakoff JA, Berman
RF, Ashwood P. Maternal immune activation and strain specific interactions in the development of autism-like behaviors
in mice. Transl Psychiatry 2013; 3: e240 [PMID: 23481627 DOI:
10.1038/tp.2013.16]
Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C,
Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999; 135: 559-563 [PMID: 10547242
DOI: 10.1016/S0022-3476(99)70052-1]
Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M,
Wick I, Bennett A, Jabado O, Hirschberg DL, Lipkin WI.
Impaired carbohydrate digestion and transport and mucosal
dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One 2011; 6: e24585 [PMID:
21949732 DOI: 10.1371/journal.pone.0024585]
Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial
ecosystems therapeutics: a new paradigm in medicine?
Benef Microbes 2013; 4: 53-65 [PMID: 23257018 DOI: 10.3920/
BM2012.0039]
Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams
JB, Krajmalnik-Brown R. Reduced incidence of Prevotella
and other fermenters in intestinal microflora of autistic
children. PLoS One 2013; 8: e68322 [PMID: 23844187 DOI:
10.1371/journal.pone.0068322]
Montiel-Castro AJ, González-Cervantes RM, Bravo-Ruiseco
G, Pacheco-López G. The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci
2013; 7: 70 [PMID: 24109440 DOI: 10.3389/fnint.2013.00070]
Aroniadis OC, Brandt LJ. Fecal microbiota transplantation:
past, present and future. Curr Opin Gastroenterol 2013; 29: 79-84

August 7, 2014|Volume 20|Issue 29|

Samsam M et al . Gastrointestinal and immune involvement in autism

92

93

94

95

96
97

98

99

100
101

102

103

104

105

[PMID: 23041678 DOI: 10.1097/MOG.0b013e32835a4b3e]
Gondalia SV, Palombo EA, Knowles SR, Cox SB, Meyer D,
Austin DW. Molecular characterisation of gastrointestinal
microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. Autism
Res 2012; 5: 419-427 [PMID: 22997101 DOI: 10.1002/aur.1253]
Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens
BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and
neurotrophins in neonatal blood of children with autism
or mental retardation. Ann Neurol 2001; 49: 597-606 [PMID:
11357950 DOI: 10.1002/ana.1024]
Hautmann M, Friis UG, Desch M, Todorov V, Castrop H,
Segerer F, Otto C, Schütz G, Schweda F. Pituitary adenylate
cyclase-activating polypeptide stimulates renin secretion
via activation of PAC1 receptors. J Am Soc Nephrol 2007; 18:
1150-1156 [PMID: 17360952 DOI: 10.1681/ASN.2006060633]
Burian B, Ortner A, Prassl R, Zimmer A, Mosgoeller W.
Clinical potential of VIP by modified pharmaco-kinetics and
delivery mechanisms. Endocr Metab Immune Disord Drug
Targets 2012; 12: 344-350 [PMID: 23094831 DOI: 10.2174/1871
53012803832594]
Edvinsson L. Sensory nerves in man and their role in primary headaches. Cephalalgia 2001; 21: 761-764 [PMID: 11595008
DOI: 10.1046/j.1468-2982.2001.00245.x]
Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13: 1113-1139
[PMID: 17430175 DOI: 10.2174/138161207780618966]
Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA.
Role of neuropeptides in migraine; where do they stand in
the latest expert recommendations in migraine treatment?
Drug Devel Res 2007; 68: 298- 314 [DOI: 10.1002/ddr.20193]
Chandrasekharan B, Nezami BG, Srinivasan S. Emerging
neuropeptide targets in inflammation: NPY and VIP. Am J
Physiol Gastrointest Liver Physiol 2013; 304: G949-G957 [PMID:
23538492 DOI: 10.1152/ajpgi.00493.2012]
Kafitz KW, Rose CR, Thoenen H, Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature
1999; 401: 918-921 [PMID: 10553907 DOI: 10.1038/44847]
Ray MT, Shannon Weickert C, Webster MJ. Decreased
BDNF and TrkB mRNA expression in multiple cortical areas
of patients with schizophrenia and mood disorders. Transl
Psychiatry 2014; 4: e389 [PMID: 24802307 DOI: 10.1038/
tp.2014.26]
Scattoni ML, Martire A, Cartocci G, Ferrante A, Ricceri L.
Reduced social interaction, behavioural flexibility and BDNF
signalling in the BTBR T+ tf/J strain, a mouse model of autism. Behav Brain Res 2013; 251: 35-40 [PMID: 23270976 DOI:
10.1016/j.bbr.2012.12.028]
Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and
future directions. Psychiatry Clin Neurosci 2010; 64: 341-357
[PMID: 20653908 DOI: 10.1111/j.1440-1819.2010.02113.x]
Taurines R, Segura M, Schecklmann M, Albantakis L,
Grünblatt E, Walitza S, Jans T, Lyttwin B, Haberhausen M,
Theisen FM, Martin B, Briegel W, Thome J, Schwenck C,
Romanos M, Gerlach M. Altered peripheral BDNF mRNA
expression and BDNF protein concentrations in blood of
children and adolescents with autism spectrum disorder. J
Neural Transm 2014; Epub ahead of print [PMID: 24500031]
Weidner KL, Buenaventura DF, Chadman KK. Mice over-

106

107

108
109
110

111

112

113

114

115

116

117

expressing BDNF in forebrain neurons develop an altered
behavioral phenotype with age. Behav Brain Res 2014; 268:
222-228 [PMID: 24768643 DOI: 10.1016/j.bbr.2014.04.025]
Singh KK, Park KJ, Hong EJ, Kramer BM, Greenberg ME,
Kaplan DR, Miller FD. Developmental axon pruning mediated by BDNF-p75NTR-dependent axon degeneration. Nat
Neurosci 2008; 11: 649-658 [PMID: 18382462 DOI: 10.1038/
nn.2114]
Fouad K, Bennett DJ, Vavrek R, Blesch A. Long-term viral
brain-derived neurotrophic factor delivery promotes spasticity in rats with a cervical spinal cord hemisection. Front Neurol
2013; 4: 187 [PMID: 24312075 DOI: 10.3389/fneur.2013.00187]
Jänisch W, Engel U, Leonhardt T. [Diffuse primary leptomeningeal gliomatosis]. Zentralbl Pathol 1991; 137: 523-530
[PMID: 1805932 DOI: 10.1038/sj.bjp.0707509]
Behrens MM, Strasser U, Lobner D, Dugan LL. Neurotrophin-mediated potentiation of neuronal injury. Microsc Res Tech
1999; 45: 276-284 [PMID: 10383120]
Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT,
Balkowiec A. Calcitonin gene-related peptide enhances
release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 2006; 99: 1338-1350
[PMID: 17064360 DOI: 10.1111/j.1471-4159.2006.04161.x]
Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy
JK, Blute VM, Taylor CJ, Ghosh S, Price TJ. BDNF regulates
atypical PKC at spinal synapses to initiate and maintain a
centralized chronic pain state. Mol Pain 2013; 9: 12 [PMID:
23510079 DOI: 10.1186/1744-8069-9-12]
Takeda M, Takahashi M, Kitagawa J, Kanazawa T, Nasu
M, Matsumoto S. Brain-derived neurotrophic factor enhances the excitability of small-diameter trigeminal ganglion neurons projecting to the trigeminal nucleus interpolaris/caudalis transition zone following masseter muscle
inflammation. Mol Pain 2013; 9: 49 [PMID: 24073832 DOI:
10.1186/1744-8069-9-49]
Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA,
Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal
trigeminal nucleus of the rat during electrical stimulation
of the trigeminal ganglion. Pain 2000; 84: 389-395 [PMID:
10666545 DOI: 10.1016/S0304-3959(99)00240-7]
Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem
2012; 12: 158-172 [PMID: 22533510 DOI: 10.2174/1871524128
02430147]
Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini
M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with
and without aura assessed both interictally and ictally.
Cephalalgia 1995; 15: 384-390 [PMID: 8536297 DOI: 10.1046/
j.1468-29821995.1505384.x]
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide
receptor antagonist BIBN 4096 BS for the acute treatment of
migraine. N Engl J Med 2004; 350: 1104-1110 [PMID: 15014183
DOI: 10.1056/NEJMoa030505]
Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ,
Lines CR, Rapoport AM. Randomized controlled trial of an
oral CGRP receptor antagonist, MK-0974, in acute treatment
of migraine. Neurology 2008; 70: 1304-1312 [PMID: 17914062
DOI: 10.1212/01.WNL.0000286940.29755.61]

P- Reviewer: Gonzalez-Reimers E, Siddiqi SA S- Editor: Qi Y
L- Editor: A E- Editor: Wang CH

WJG|www.wjgnet.com

9951

August 7, 2014|Volume 20|Issue 29|

Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

I S S N 1 0  0 7  -   9  3 2  7
29

9   7 7 10  0 7   9 3 2 0 45

© 2014 Baishideng Publishing Group Inc. All rights reserved.

